ClinicalTrials.gg
CompletedNCT03626662Updated Jan 28, 2026Results posted

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)

A Phase 1 interventional study of AMG 890 and Placebo in Cardiovascular Disease, sponsored by Amgen. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Amgen · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in subjects with elevated plasma Lipoprotein(a) [Lp(a)]. AMG 890 will be evaluated in approximately 80 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.

02

Conditions studied

  • Cardiovascular Disease
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 79 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women with ages between 18 and 70 years old, inclusive.
  • Protocol-defined elevated plasma Lp(a) level.
  • (BMI) greater than or equal to 18 and less than or equal to 40 kg/m2, at screening.
  • Women must be of non-.
  • Other Inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Currently receiving treatment in another device or drug study.
  • Women who are lactating/breastfeeding or who plan to breastfeed while on study or through 90 days after receiving the last dose of investigational product (for subjects who withdraw prior to end of study).
  • History or evidence of a disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  • History or clinical evidence of bleeding diathesis or any coagulation disorder.
  • History or clinical evidence of peripheral neuropathy.
  • Other Exclusion criteria may apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
79 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Single Ascending Dose Cohorts

    Drug: Placebo

  • Experimental
    AMG 890

    Single Ascending Dose Cohorts

    Drug: AMG 890

Interventions

  • Ascending Single Doses of AMG 890

  • DrugPlacebo

    Calculated volume to match experimental drug.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

    An adverse event was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was defined as any event with onset after the administration of the first dose of investigational product and up to and including the end of treatment date, or end of trial for participants who discontinued the trial during the treatment period. Clinically significant changes in vital signs, electrocardiograms (ECGs), and safety laboratory analytes were included as TEAEs.

    Time frame: From first dose of trial until the end of trial; median (min, max) duration was 8.54 (0.23, 23.92) months

Secondary outcomes

  1. Maximum Observed Concentration (Cmax) of Olpasiran

    Blood samples were collected for measurement of serum concentrations of Olpasiran.

    Time frame: Cohorts 1-5:pre-dose, Days 1-4, 7, 15, 29, 57, 85 post-dose; Cohorts 6-7:pre-dose, Days 1, 2, 4, 7, 15 post-dose; Cohort 8:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113 post-dose; Cohort 9:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113, 155 post-dose

  2. Time to Reach Cmax (Tmax) of Olpasiran

    Blood samples were collected for measurement of serum concentrations of Olpasiran.

    Time frame: Cohorts 1-5:pre-dose, Days 1-4, 7, 15, 29, 57, 85 post-dose; Cohorts 6-7:pre-dose, Days 1, 2, 4, 7, 15 post-dose; Cohort 8:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113 post-dose; Cohort 9:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113, 155 post-dose

  3. Area Under the Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Timepoint (AUC0-last) of Olpasiran

    Blood samples were collected for measurement of serum concentrations of Olpasiran.

    Time frame: Cohorts 1-5:pre-dose, Days 1-4, 7, 15, 29, 57, 85 post-dose; Cohorts 6-7:pre-dose, Days 1, 2, 4, 7, 15 post-dose; Cohort 8:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113 post-dose; Cohort 9:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113, 155 post-dose

  4. Change From Baseline in Plasma Lp(a) Levels

    Change from baseline for plasma Lp(a) by cohort and at scheduled time points were presented.

    Time frame: Cohorts 1-2:Baseline,Days 2,4,7,15,18,22,29,43,57,71,85,113;3-5:Baseline,Days 2,4,7,15,18,22,29,43,57,71,85,113,155,183,225;6-7:Baseline,Days 2,4,7,15,29,43,57,85,113,155,183,225;8-9:Baseline,Days 2,4,7,15,29,43,57,85,113,155,183,225,253,281,309,337,365

  5. Percent Change From Baseline in Plasma Lp(a) Levels

    Percent change from baseline for plasma Lp(a) by cohort and at scheduled time points during the treatment period were presented.

    Time frame: Cohorts 1-2:Baseline,Days 2,4,7,15,18,22,29,43,57,71,85,113;3-5:Baseline,Days 2,4,7,15,18,22,29,43,57,71,85,113,155,183,225;6-7:Baseline,Days 2,4,7,15,29,43,57,85,113,155,183,225;8-9:Baseline,Days 2,4,7,15,29,43,57,85,113,155,183,225,253,281,309,337,365

07

Results

Posted Jan 28, 2026

Participant flow

Participants were enrolled at 8 research centers in the United States (US) and Australia between July 2018 and April 2023.

Participant flow — Overall Study
MilestonePlaceboCohort 1: Olpasiran 3 mgCohort 2: Olpasiran 9 mgCohort 3: Olpasiran 30 mgCohort 4 Olpasiran: 75 mgCohort 5 Olpasiran: 225 mgCohort 6: Olpasiran 9 mgCohort 7: Olpasiran 75 mgCohort 8: Olpasiran 225 mgCohort 9: Olpasiran 675 mg
Started20666669956
Participants who received placebo in cohorts 1-510000000000
Participants who received placebo in cohorts 6-910000000000
Completed17646238655
Not completed3020431301
Withdrew: Withdrawal of consent from study2000430001
Withdrew: Decision by sponsor0000001300
Withdrew: Lost to follow-up1020000000

Outcome measures

PrimaryNumber of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

An adverse event was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was defined as any event with onset after the administration of the first dose of investigational product and up to and including the end of treatment date, or end of trial for participants who discontinued the trial during the treatment period. Clinically significant changes in vital signs, electrocardiograms (ECGs), and safety laboratory analytes were included as TEAEs.

Time frame:
From first dose of trial until the end of trial; median (min, max) duration was 8.54 (0.23, 23.92) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
ParticipantsCohorts 1-5: PlaceboCohort 1: Olpasiran 3 mgCohort 2: Olpasiran 9 mgCohort 3: Olpasiran 30 mgCohort 4 Olpasiran: 75 mgCohort 5 Olpasiran: 225 mgCohorts 6-9: PlaceboCohort 6: Olpasiran 9 mgCohort 7: Olpasiran 75 mgCohort 8: Olpasiran 225 mgCohort 9: Olpasiran 675 mg
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)53351076344
SecondaryMaximum Observed Concentration (Cmax) of Olpasiran

Blood samples were collected for measurement of serum concentrations of Olpasiran.

Time frame:
Cohorts 1-5:pre-dose, Days 1-4, 7, 15, 29, 57, 85 post-dose; Cohorts 6-7:pre-dose, Days 1, 2, 4, 7, 15 post-dose; Cohort 8:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113 post-dose; Cohort 9:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113, 155 post-dose
Reported as:
Mean · ng/mL
Maximum Observed Concentration (Cmax) of Olpasiran
ng/mLCohort 1: Olpasiran 3 mgCohort 2: Olpasiran 9 mgCohort 3: Olpasiran 30 mgCohort 4 Olpasiran: 75 mgCohort 5 Olpasiran: 225 mgCohort 6: Olpasiran 9 mgCohort 7: Olpasiran 75 mgCohort 8: Olpasiran 225 mgCohort 9: Olpasiran 675 mg
Maximum Observed Concentration (Cmax) of Olpasiran11.7 ± 2.3636.1 ± 19.774.9 ± 25252 ± 153421 ± 22317.4 ± 7.48111 ± 56.31390 ± 9472620 ± 888
SecondaryTime to Reach Cmax (Tmax) of Olpasiran

Blood samples were collected for measurement of serum concentrations of Olpasiran.

Time frame:
Cohorts 1-5:pre-dose, Days 1-4, 7, 15, 29, 57, 85 post-dose; Cohorts 6-7:pre-dose, Days 1, 2, 4, 7, 15 post-dose; Cohort 8:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113 post-dose; Cohort 9:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113, 155 post-dose
Reported as:
Median · hours
Time to Reach Cmax (Tmax) of Olpasiran
hoursCohort 1: Olpasiran 3 mgCohort 2: Olpasiran 9 mgCohort 3: Olpasiran 30 mgCohort 4 Olpasiran: 75 mgCohort 5 Olpasiran: 225 mgCohort 6: Olpasiran 9 mgCohort 7: Olpasiran 75 mgCohort 8: Olpasiran 225 mgCohort 9: Olpasiran 675 mg
Time to Reach Cmax (Tmax) of Olpasiran3.0 (1.0 to 9.0)3.0 (3.0 to 6.0)7.5 (1.0 to 9.0)4.5 (0.17 to 9.0)6.0 (1.0 to 12)3.0 (1.0 to 9.0)6.0 (3.0 to 24)3.0 (1.0 to 23)4.5 (2.1 to 6.2)
SecondaryArea Under the Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Timepoint (AUC0-last) of Olpasiran

Blood samples were collected for measurement of serum concentrations of Olpasiran.

Time frame:
Cohorts 1-5:pre-dose, Days 1-4, 7, 15, 29, 57, 85 post-dose; Cohorts 6-7:pre-dose, Days 1, 2, 4, 7, 15 post-dose; Cohort 8:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113 post-dose; Cohort 9:pre-dose, Days 1, 2, 4, 7, 15, 29, 57, 85, 113, 155 post-dose
Reported as:
Mean · hour*ng/mL
Area Under the Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Timepoint (AUC0-last) of Olpasiran
hour*ng/mLCohort 1: Olpasiran 3 mgCohort 2: Olpasiran 9 mgCohort 3: Olpasiran 30 mgCohort 4 Olpasiran: 75 mgCohort 5 Olpasiran: 225 mgCohort 6: Olpasiran 9 mgCohort 7: Olpasiran 75 mgCohort 8: Olpasiran 225 mgCohort 9: Olpasiran 675 mg
Area Under the Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Timepoint (AUC0-last) of Olpasiran116 ± 39.8352 ± 1411020 ± 3292830 ± 7307800 ± 1670240 ± 96.32060 ± 64229600 ± 2350044800 ± 16400
SecondaryChange From Baseline in Plasma Lp(a) Levels

Change from baseline for plasma Lp(a) by cohort and at scheduled time points were presented.

Time frame:
Cohorts 1-2:Baseline,Days 2,4,7,15,18,22,29,43,57,71,85,113;3-5:Baseline,Days 2,4,7,15,18,22,29,43,57,71,85,113,155,183,225;6-7:Baseline,Days 2,4,7,15,29,43,57,85,113,155,183,225;8-9:Baseline,Days 2,4,7,15,29,43,57,85,113,155,183,225,253,281,309,337,365
Reported as:
Mean · nmol/L
Change From Baseline in Plasma Lp(a) Levels
nmol/LCohorts 1-5: PlaceboCohort 1: Olpasiran 3 mgCohort 2: Olpasiran 9 mgCohort 3: Olpasiran 30 mgCohort 4 Olpasiran: 75 mgCohort 5 Olpasiran: 225 mgCohorts 6-9: PlaceboCohort 6: Olpasiran 9 mgCohort 7: Olpasiran 75 mgCohort 8: Olpasiran 225 mgCohort 9: Olpasiran 675 mg
Change from baseline to Day 29.740 ± 11.415-17.820 ± 16.662-1.417 ± 9.4099.412 ± 13.2401.937 ± 2.589-6.438 ± 14.001-54.862 ± 91.381-4.886 ± 24.160-15.119 ± 79.070-88.586 ± 105.991-86.940 ± 134.234
Change from baseline to Day 411.450 ± 13.155-13.020 ± 17.499-8.317 ± 13.2713.862 ± 12.344-23.080 ± 12.246-13.455 ± 11.489-55.527 ± 100.807-33.358 ± 21.037-49.659 ± 70.520-116.986 ± 71.397-146.718 ± 165.278
Change from baseline to Day 70.410 ± 12.785-24.170 ± 21.798-35.283 ± 13.307-32.272 ± 7.480-45.863 ± 8.095-69.188 ± 35.265-32.389 ± 99.479-77.707 ± 47.138-102.508 ± 75.135-203.215 ± 112.549-204.990 ± 159.912
Change from baseline to Day 15-2.530 ± 16.293-59.137 ± 28.794-76.094 ± 22.915-63.772 ± 10.074-96.580 ± 11.663-98.938 ± 30.749-35.367 ± 54.976-138.618 ± 38.215-208.459 ± 81.219-277.226 ± 135.590-294.890 ± 176.007
Change from baseline to Day 18-6.940 ± 15.926-71.070 ± 26.156-85.594 ± 24.516-76.222 ± 13.730-108.463 ± 16.162-122.205 ± 30.732—————
Change from baseline to Day 22-3.450 ± 14.989-77.853 ± 25.502-93.714 ± 22.458-79.388 ± 15.566-117.813 ± 19.714-126.788 ± 32.793—————
Change from baseline to Day 29-1.350 ± 14.355-82.037 ± 26.703-104.894 ± 26.885-86.038 ± 18.938-124.713 ± 23.769-134.605 ± 36.395-46.909 ± 72.951-188.740 ± 37.700-270.641 ± 95.753-330.115 ± 171.096-366.214 ± 199.738
Change from baseline to Day 43-7.720 ± 14.629-89.787 ± 25.866-108.734 ± 28.948-90.072 ± 20.412-129.230 ± 25.491-140.572 ± 36.947-33.244 ± 64.989-197.673 ± 36.630-282.841 ± 95.711-257.585 ± 30.464-351.707 ± 193.404
Change from baseline to Day 572.620 ± 11.739-87.220 ± 29.478-106.834 ± 27.834-89.955 ± 20.435-129.513 ± 26.035-140.922 ± 36.663-27.973 ± 104.520-200.251 ± 40.105-288.874 ± 100.724-331.386 ± 166.191-353.207 ± 193.827
Change from baseline to Day 71-0.392 ± 14.313-83.970 ± 24.076-97.518 ± 24.356-88.805 ± 22.440-128.797 ± 26.709-140.572 ± 37.216—————
Change from baseline to Day 852.497 ± 12.877-73.953 ± 23.337-96.318 ± 23.377-85.072 ± 21.123-127.980 ± 27.181-139.255 ± 36.247-35.246 ± 98.490-185.407 ± 42.933-275.519 ± 95.029-330.806 ± 167.145-352.923 ± 194.316
Change from baseline to Day 1134.697 ± 6.955-63.103 ± 28.733-89.168 ± 24.019-82.338 ± 24.960-123.147 ± 26.883-137.038 ± 36.491-26.599 ± 83.420-162.829 ± 50.183-253.641 ± 93.836-325.526 ± 168.995-276.696 ± 75.437
Change from baseline to Day 155-13.990 ± 14.136——-63.566 ± 26.356-123.076 ± 29.946-144.877 ± 24.157-32.339 ± 101.724-132.696 ± 52.950-195.725 ± 50.429-304.846 ± 173.370-368.258 ± 212.962
Change from baseline to Day 183-20.770 ± 10.748———-109.435 ± 31.304-140.143 ± 25.143-32.749 ± 77.047-109.740 ± 41.868-176.781 ± 51.330-291.966 ± 167.126-338.990 ± 202.609
Change from baseline to Day 225-3.902 ± 18.584——-64.100 ± NA-104.285 ± 36.607-111.892 ± 27.648-15.849 ± 70.823-85.218 ± 39.572-165.297 ± 89.184-257.226 ± 167.618-320.223 ± 207.672
Change from baseline to Day 253——————-101.640 ± 58.930——-276.490 ± 179.094-318.725 ± 259.063
Change from baseline to Day 281——————-96.107 ± 81.127——-230.106 ± 164.525-308.138 ± 230.671
Change from baseline to Day 309——————-117.353 ± 34.739——-215.726 ± 168.115-299.218 ± 232.143
Change from baseline to Day 337——————-113.073 ± 84.006——-198.440 ± 162.932-279.478 ± 231.897
Change from baseline to Day 365——————-81.653 ± 81.061——-170.126 ± 146.154-165.656 ± 88.637
SecondaryPercent Change From Baseline in Plasma Lp(a) Levels

Percent change from baseline for plasma Lp(a) by cohort and at scheduled time points during the treatment period were presented.

Time frame:
Cohorts 1-2:Baseline,Days 2,4,7,15,18,22,29,43,57,71,85,113;3-5:Baseline,Days 2,4,7,15,18,22,29,43,57,71,85,113,155,183,225;6-7:Baseline,Days 2,4,7,15,29,43,57,85,113,155,183,225;8-9:Baseline,Days 2,4,7,15,29,43,57,85,113,155,183,225,253,281,309,337,365
Reported as:
Mean · percent change
Percent Change From Baseline in Plasma Lp(a) Levels
percent changeCohorts 1-5: PlaceboCohort 1: Olpasiran 3 mgCohort 2: Olpasiran 9 mgCohort 3: Olpasiran 30 mgCohort 4 Olpasiran: 75 mgCohort 5 Olpasiran: 225 mgCohorts 6-9: PlaceboCohort 6: Olpasiran 9 mgCohort 7: Olpasiran 75 mgCohort 8: Olpasiran 225 mgCohort 9: Olpasiran 675 mg
Percent change from baseline to Day 28.407 ± 8.491-13.943 ± 11.951-1.094 ± 7.6998.295 ± 13.6651.415 ± 1.925-4.027 ± 9.484-13.633 ± 21.683-1.570 ± 10.443-2.088 ± 20.604-21.583 ± 17.410-15.998 ± 20.674
Percent change from baseline to Day 411.483 ± 13.532-9.649 ± 12.452-6.487 ± 10.5772.462 ± 12.152-17.185 ± 7.985-8.416 ± 5.613-14.608 ± 23.141-12.800 ± 8.339-13.391 ± 16.046-34.553 ± 16.231-30.307 ± 21.326
Percent change from baseline to Day 70.684 ± 10.535-17.968 ± 15.135-30.135 ± 14.583-34.017 ± 13.052-34.398 ± 4.843-46.725 ± 15.401-7.196 ± 21.378-29.518 ± 15.778-30.979 ± 14.986-58.222 ± 13.332-53.069 ± 12.226
Percent change from baseline to Day 15-1.586 ± 13.188-46.805 ± 17.609-61.995 ± 9.342-65.000 ± 15.685-72.512 ± 5.451-69.051 ± 15.864-8.425 ± 12.997-53.145 ± 15.700-66.742 ± 7.852-82.712 ± 7.795-81.166 ± 5.437
Percent change from baseline to Day 18-5.992 ± 12.779-56.826 ± 15.047-69.643 ± 6.846-76.332 ± 12.228-81.178 ± 6.122-84.107 ± 3.792—————
Percent change from baseline to Day 22-3.064 ± 11.850-62.268 ± 12.534-77.121 ± 9.413-79.157 ± 11.601-87.780 ± 2.887-87.062 ± 2.254—————
Percent change from baseline to Day 29-1.630 ± 11.948-65.771 ± 14.454-85.794 ± 7.534-85.001 ± 8.595-92.577 ± 1.368-92.124 ± 3.106-14.805 ± 19.160-72.210 ± 15.684-85.371 ± 7.046-95.448 ± 2.665-95.872 ± 1.879
Percent change from baseline to Day 43-6.503 ± 11.507-72.060 ± 12.238-88.761 ± 7.479-88.558 ± 6.473-95.843 ± 1.293-96.365 ± 2.122-12.075 ± 21.690-75.430 ± 14.252-89.637 ± 5.632-98.226 ± 0.645-98.499 ± 0.676
Percent change from baseline to Day 571.259 ± 10.313-70.163 ± 17.697-87.421 ± 9.001-88.472 ± 6.147-96.014 ± 2.073-96.685 ± 1.316-4.878 ± 25.711-76.174 ± 13.755-91.230 ± 6.742-98.547 ± 0.677-98.956 ± 0.400
Percent change from baseline to Day 71-1.546 ± 12.389-67.809 ± 13.524-89.962 ± 4.968-86.866 ± 5.779-95.383 ± 2.145-96.332 ± 1.963—————
Percent change from baseline to Day 851.275 ± 11.569-59.413 ± 12.808-88.913 ± 4.425-83.628 ± 8.427-94.747 ± 3.108-95.517 ± 2.334-7.875 ± 20.770-70.536 ± 15.558-87.328 ± 7.434-98.275 ± 0.948-98.814 ± 0.608
Percent change from baseline to Day 1133.430 ± 7.307-49.873 ± 16.496-82.051 ± 7.297-79.916 ± 11.140-91.351 ± 6.866-93.926 ± 2.891-6.786 ± 24.282-61.542 ± 17.396-80.484 ± 11.668-96.381 ± 3.343-97.963 ± 1.142
Percent change from baseline to Day 155-15.206 ± 14.391——-56.571 ± 13.156-86.424 ± 11.607-88.415 ± 3.561-7.233 ± 28.936-50.331 ± 20.523-68.537 ± 15.584-89.181 ± 10.167-95.757 ± 4.528
Percent change from baseline to Day 183-22.300 ± 6.289———-76.956 ± 26.029-85.437 ± 4.356-7.884 ± 23.516-41.792 ± 16.749-60.178 ± 18.037-85.355 ± 11.214-93.357 ± 5.554
Percent change from baseline to Day 225-4.934 ± 17.577——-84.342 ± NA-73.464 ± 29.532-81.880 ± 11.062-4.730 ± 23.419-32.228 ± 14.640-51.725 ± 20.701-73.722 ± 17.160-86.702 ± 12.646
Percent change from baseline to Day 253——————-24.858 ± 11.199——-76.579 ± 15.153-80.199 ± 18.262
Percent change from baseline to Day 281——————-23.787 ± 22.538——-64.718 ± 19.802-75.169 ± 20.243
Percent change from baseline to Day 309——————-31.515 ± 2.142——-59.631 ± 21.986-72.336 ± 19.971
Percent change from baseline to Day 337——————-26.688 ± 15.875——-52.066 ± 26.070-66.022 ± 23.528
Percent change from baseline to Day 365——————-19.333 ± 15.319——-46.309 ± 23.019-56.484 ± 19.999

Adverse events

Collected over For all-cause mortality, from randomization until the end of trial completion; median (min, max) time on trial was 8.57 (0.26, 23.95) months. For AE, from first dose of trial drug until the end of trial; median (min, max) duration was 8.54 (0.23, 23.92) months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohorts 1-5: Placebo0/10 (0%)0/10 (0%)5/10 (50%)
Cohorts 6-9: Placebo0/10 (0%)1/10 (10%)7/10 (70%)
Cohort 1: Olpasiran 3 mg0/6 (0%)0/6 (0%)3/6 (50%)
Cohort 2: Olpasiran 9 mg0/6 (0%)0/6 (0%)3/6 (50%)
Cohort 3: Olpasiran 30 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Cohort 4 Olpasiran: 75 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Cohort 5 Olpasiran: 225 mg0/6 (0%)0/6 (0%)0/6 (0%)
Cohort 6: Olpasiran 9 mg0/9 (0%)0/9 (0%)6/9 (66.7%)
Cohort 7: Olpasiran 75 mg0/9 (0%)0/9 (0%)3/9 (33.3%)
Cohort 8: Olpasiran 225 mg0/5 (0%)0/5 (0%)4/5 (80%)
Cohort 9: Olpasiran 675 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent serious events
Most frequent serious events
EventCohorts 1-5: PlaceboCohorts 6-9: PlaceboCohort 1: Olpasiran 3 mgCohort 2: Olpasiran 9 mgCohort 3: Olpasiran 30 mgCohort 4 Olpasiran: 75 mgCohort 5 Olpasiran: 225 mgCohort 6: Olpasiran 9 mgCohort 7: Olpasiran 75 mgCohort 8: Olpasiran 225 mgCohort 9: Olpasiran 675 mg
Non-cardiac chest painGeneral disorders0/101/100/60/60/60/60/60/90/90/50/6
Cardiac telemetry abnormalInvestigations0/101/100/60/60/60/60/60/90/90/50/6
Most frequent other events
Showing 10 of 64
Most frequent other events
EventCohorts 1-5: PlaceboCohorts 6-9: PlaceboCohort 1: Olpasiran 3 mgCohort 2: Olpasiran 9 mgCohort 3: Olpasiran 30 mgCohort 4 Olpasiran: 75 mgCohort 5 Olpasiran: 225 mgCohort 6: Olpasiran 9 mgCohort 7: Olpasiran 75 mgCohort 8: Olpasiran 225 mgCohort 9: Olpasiran 675 mg
Urinary tract infectionInfections and infestations0/100/100/60/60/60/60/60/90/92/50/6
Upper respiratory tract infectionInfections and infestations1/101/102/60/62/60/60/62/90/90/50/6
HeadacheNervous system disorders1/103/100/60/60/60/60/62/92/90/50/6
Abdominal discomfortGastrointestinal disorders0/100/100/60/60/60/60/60/90/91/50/6
Injection site haemorrhageGeneral disorders0/100/100/60/60/60/60/60/90/91/50/6
Injection site painGeneral disorders0/100/100/60/60/60/60/60/90/91/51/6
COVID-19Infections and infestations0/100/100/60/60/60/60/60/90/91/50/6
CystitisInfections and infestations0/100/100/60/60/60/60/60/90/91/50/6
GastroenteritisInfections and infestations0/101/100/60/60/60/60/60/90/91/50/6
SinusitisInfections and infestations0/101/100/60/60/60/60/60/90/91/50/6

Baseline characteristics

The safety analysis set consisted of all participants who received at least 1 dose of Olpasiran or placebo.

Age, Continuous
Age, Continuous(years)PlaceboCohort 1: Olpasiran 3 mgCohort 2: Olpasiran 9 mgCohort 3: Olpasiran 30 mgCohort 4 Olpasiran: 75 mgCohort 5 Olpasiran: 225 mgCohort 6: Olpasiran 9 mgCohort 7: Olpasiran 75 mgCohort 8: Olpasiran 225 mgCohort 9: Olpasiran 675 mgTotal
Mean52.0 ± 8.842.7 ± 16.050.2 ± 7.634.5 ± 11.551.5 ± 13.440.8 ± 14.352.7 ± 10.852.8 ± 8.358.2 ± 4.347.7 ± 13.149.2 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCohort 1: Olpasiran 3 mgCohort 2: Olpasiran 9 mgCohort 3: Olpasiran 30 mgCohort 4 Olpasiran: 75 mgCohort 5 Olpasiran: 225 mgCohort 6: Olpasiran 9 mgCohort 7: Olpasiran 75 mgCohort 8: Olpasiran 225 mgCohort 9: Olpasiran 675 mgTotal
Female932130334129
Male1134536661550
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCohort 1: Olpasiran 3 mgCohort 2: Olpasiran 9 mgCohort 3: Olpasiran 30 mgCohort 4 Olpasiran: 75 mgCohort 5 Olpasiran: 225 mgCohort 6: Olpasiran 9 mgCohort 7: Olpasiran 75 mgCohort 8: Olpasiran 225 mgCohort 9: Olpasiran 675 mgTotal
Hispanic or Latino866412230032
Not Hispanic or Latino1200254765647
Unknown or Not Reported00000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboCohort 1: Olpasiran 3 mgCohort 2: Olpasiran 9 mgCohort 3: Olpasiran 30 mgCohort 4 Olpasiran: 75 mgCohort 5 Olpasiran: 225 mgCohort 6: Olpasiran 9 mgCohort 7: Olpasiran 75 mgCohort 8: Olpasiran 225 mgCohort 9: Olpasiran 675 mgTotal
American Indian or Alaska Native00000010001
Asian00000000000
Native Hawaiian or Other Pacific Islander00000000000
Black or African American340131100114
White1626535795563
More than one race00000000000
Unknown or Not Reported10000000001
08

Study locations

9 sites
  • Orange County Research Center
    Tustin, California 92780, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • QPS Miami Research Associates
    South Miami, Florida 33143, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • New York University
    New York, New York 10016, United States
  • Medpace Inc
    Cincinnati, Ohio 45227, United States
  • Clinical Medical and Analytical eXellence CMAX
    Adelaide, South Australia 5000, Australia
  • Linear Clinical Research Limited
    Nedlands, Western Australia 6009, Australia
09

References and documents

Publications

  • Koren MJ, Moriarty PM, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, Florio M, Kassahun H, Melquist S, Varrieur T, Haldar SM, Sohn W, Wang H, Elliott-Davey M, Rock BM, Pei T, Homann O, Hellawell J, Watts GF. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med. 2022 Jan;28(1):96-103. doi: 10.1038/s41591-021-01634-w. Epub 2022 Jan 13. PubMed 35027752 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Apr 2023, 56 months.

Results were first posted in Jan 2026, 2 years 9 months after primary completion.

Of 53 industry-sponsored phase 1 interventional studies under Cardiovascular Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 15. This study's 56 months is above that.

Counting every sponsor, half of 96 studies reached it within 15 months; a quarter within 3 and three quarters within 45.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2018
First posted
Aug 13, 2018
StartActual
Jul 30, 2018
Primary completionActual
Apr 18, 2023
CompletionActual
Apr 18, 2023
Results first posted
Jan 28, 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03626662
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 13, 2018
Start date
Jul 30, 2018
Primary completion
Apr 18, 2023
Completion
Apr 18, 2023
Results posted
Jan 28, 2026
Last update
Jan 28, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olpasiran

Start the discussion